Promethera persuades Shire and Boehringer to invest in cell therapy

Promethera Biosciences, a Belgian cell therapy company, has raised €23.6 million: €17 million in venture capital and €6.6 million in grants and refundable loans. New investors include the venture arms of Boehringer Ingelheim and Shire, Japanese investment fund Mitsui Global Investment, US company ATMI (a specialty materials provider) and Belgian VC fund Sambrinvest.